RxDoctor Payments Data

Lynn Waggoner, MD

Cardiovascular Disease · Spokane, WANPI 1326091349

Payments from drug & device makers

$4,509in general payments, 2019–2025

Across 120 payments — averaging $37.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Johnson & Johnson$401
  • Amgen$352
  • Novo Nordisk$335
  • Boehringer Ingelheim$290
  • Heartflow, Inc.$213
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$3,009100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,509 in reported general payments places this provider in the 75th percentile of 370 cardiovascular disease providers in Washington.

See all cardiovascular disease providers in Washington

Medicare billing

Part B allowed, 2024
$252,092
Medicare patients
1,124
Services billed
3,791

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban412$442,609
XareltoRivaroxaban105$134,338
Repatha SureclickEvolocumab105$88,759
JardianceEmpagliflozin84$78,863
EntrestoSacubitril/Valsartan43$62,072
FarxigaDapagliflozin Propanediol32$31,274
MounjaroTirzepatide15$17,399
Repatha SyringeEvolocumab23$14,408
Ezetimibe268$7,533
Atorvastatin Calcium564$7,037
Praluent PenAlirocumab13$6,234
Metoprolol Succinate455$6,209
Rosuvastatin Calcium285$5,544
Carvedilol441$3,639
Potassium Chloride145$3,286

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$196$442,609412 claims
Johnson & JohnsonXarelto$401$134,338105 claims
Boehringer IngelheimJardiance$290$78,86384 claims
NovartisEntresto$1,894$62,07243 claims
AstraZenecaFarxiga$143$31,27432 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 370 cardiovascular disease providers in Washington.

Other cardiovascular disease in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →